drugset / Trial / NCT04306237

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

NCT04306237 ↗

Phase 2 Withdrawn Imbria Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of the study are to assess the safety, tolerability, and potential efficacy of IMB-1018972 on patients with refractory angina. Study will assess functional capacity employing a modified Bruce Protocol treadmill ETT, patient reports of angina symptoms via an electronic diary, and activity using an accelerometer.

Timeline

Start
2020-05-01
Primary completion
2025-02
Completion
2025-04

Outcome

Outcome not reported

Stopped: “Coronavirus pandemic”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ninerafaxstat Small molecule 200 mg Oral